Trinity Biotech plc – NASDAQ:TRIB

Trinity Biotech stock price today

$1.5
+0.69
+87.06%
Financial Health
0
1
2
3
4
5
6
7
8
9

Trinity Biotech stock price monthly change

-75.62%
month

Trinity Biotech stock price quarterly change

-75.62%
quarter

Trinity Biotech stock price yearly change

+105.64%
year

Trinity Biotech key metrics

Market Cap
9.09M
Enterprise value
N/A
P/E
-0.72
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
0.42
Price/Book
4.94
PEG ratio
N/A
EPS
-2.75
Revenue
56.70M
EBITDA
-12.77M
Income
-21.52M
Revenue Q/Q
-0.84%
Revenue Y/Y
-19.94%
Profit margin
-42.21%
Oper. margin
-18.92%
Gross margin
30.22%
EBIT margin
-18.92%
EBITDA margin
-22.54%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Trinity Biotech stock price history

Trinity Biotech stock forecast

Trinity Biotech financial statements

Trinity Biotech plc (NASDAQ:TRIB): Profit margin
Jun 2023 13.89M -5.98M -43.09%
Sep 2023 14.67M -6.72M -45.79%
Dec 2023 13.42M -5.50M -40.97%
Mar 2024 14.70M -3.31M -22.56%
Trinity Biotech plc (NASDAQ:TRIB): Analyst Estimates
Dec 2023 13.42M -5.50M -40.97%
Mar 2024 14.70M -3.31M -22.56%
Sep 2025 18.5M -1.86M -10.07%
Dec 2025 19M -1.50M -7.94%
  • Analysts Price target

  • Financials & Ratios estimates

Trinity Biotech plc (NASDAQ:TRIB): Earnings per share (EPS)
2024-05-23 -0.54 -0.37
2024-11-15 -0.54 -0.43
Trinity Biotech plc (NASDAQ:TRIB): Debt to assets
Jun 2023 71990000 83.37M 115.81%
Sep 2023 63597000 81.08M 127.5%
Dec 2023 59435000 83.38M 140.29%
Mar 2024 90305000 113.16M 125.31%
Trinity Biotech plc (NASDAQ:TRIB): Cash Flow
Jun 2023 -4.41M 27.86M -13.45M
Sep 2023 -4.66M -886K -2.43M
Dec 2023 -966K -890.99K -555K
Mar 2024 -4.82M -13.96M 20.85M

Trinity Biotech alternative data

Trinity Biotech plc (NASDAQ:TRIB): Employee count
Aug 2023 398
Sep 2023 398
Oct 2023 398
Nov 2023 398
Dec 2023 398
Jan 2024 398
Feb 2024 398
Mar 2024 398
Apr 2024 398
May 2024 398
Jun 2024 380
Jul 2024 380

Trinity Biotech other data

3.36% -1.41%
of TRIB is owned by hedge funds
4.62M -1.94M
shares is hold by hedge funds
Insider Compensation
Mr. Ronan O'Caoimh (1956) Chairman & Chief Executive Officer
$1,050,000
Mr. Kevin Tansley (1971) Executive Director
$757,000
Mr. John Gillard (1981) Chief Financial Officer, Company Sec. & Executive Director
$312,000
Dr. James Walsh Ph.D. (1958) Executive Director
$38,000
Tuesday, 24 December 2024
globenewswire.com
Wednesday, 18 December 2024
globenewswire.com
Friday, 15 November 2024
seekingalpha.com
globenewswire.com
Thursday, 14 November 2024
globenewswire.com
Thursday, 7 November 2024
globenewswire.com
Friday, 25 October 2024
globenewswire.com
globenewswire.com
Tuesday, 8 October 2024
zacks.com
Monday, 7 October 2024
globenewswire.com
Wednesday, 25 September 2024
zacks.com
Tuesday, 24 September 2024
globenewswire.com
Wednesday, 18 September 2024
globenewswire.com
Tuesday, 10 September 2024
zacks.com
Monday, 9 September 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
Monday, 26 August 2024
globenewswire.com
Tuesday, 20 August 2024
globenewswire.com
Friday, 16 August 2024
seekingalpha.com
Wednesday, 14 August 2024
globenewswire.com
Tuesday, 13 August 2024
globenewswire.com
Tuesday, 6 August 2024
globenewswire.com
Friday, 2 August 2024
globenewswire.com
Tuesday, 9 July 2024
globenewswire.com
Monday, 24 June 2024
globenewswire.com
Monday, 10 June 2024
globenewswire.com
Monday, 3 June 2024
globenewswire.com
Thursday, 23 May 2024
seekingalpha.com
globenewswire.com
Tuesday, 21 May 2024
globenewswire.com
  • What's the price of Trinity Biotech stock today?

    One share of Trinity Biotech stock can currently be purchased for approximately $1.5.

  • When is Trinity Biotech's next earnings date?

    Unfortunately, Trinity Biotech's (TRIB) next earnings date is currently unknown.

  • Does Trinity Biotech pay dividends?

    No, Trinity Biotech does not pay dividends.

  • How much money does Trinity Biotech make?

    Trinity Biotech has a market capitalization of 9.09M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 24% to 56.83M US dollars. Trinity Biotech made a loss 24.02M US dollars in net income (profit) last year or -$0.43 on an earnings per share basis.

  • What is Trinity Biotech's stock symbol?

    Trinity Biotech plc is traded on the NASDAQ under the ticker symbol "TRIB".

  • What is Trinity Biotech's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of Trinity Biotech?

    Shares of Trinity Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Trinity Biotech's key executives?

    Trinity Biotech's management team includes the following people:

    • Mr. Ronan O'Caoimh Chairman & Chief Executive Officer(age: 69, pay: $1,050,000)
    • Mr. Kevin Tansley Executive Director(age: 54, pay: $757,000)
    • Mr. John Gillard Chief Financial Officer, Company Sec. & Executive Director(age: 44, pay: $312,000)
    • Dr. James Walsh Ph.D. Executive Director(age: 67, pay: $38,000)
  • How many employees does Trinity Biotech have?

    As Jul 2024, Trinity Biotech employs 380 workers, which is 5% less then previous quarter.

  • When Trinity Biotech went public?

    Trinity Biotech plc is publicly traded company for more then 32 years since IPO on 21 Oct 1992.

  • What is Trinity Biotech's official website?

    The official website for Trinity Biotech is trinitybiotech.com.

  • How can i contact Trinity Biotech?

    Trinity Biotech can be reached via phone at +353 1 276 9800.

Trinity Biotech company profile:

Trinity Biotech plc

trinitybiotech.com
Exchange:

NASDAQ

Full time employees:

380

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

IDA Business Park
Bray, A98 H5C8

CIK: 0000888721
ISIN: US8964385046
CUSIP: 896438306